Cargando…

Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...

Descripción completa

Detalles Bibliográficos
Autores principales: Giudice, Giuseppe, Filoni, Angela, Maggio, Giulio, Bonamonte, Domenico, Vestita, Michelangelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://www.ncbi.nlm.nih.gov/pubmed/28293640
http://dx.doi.org/10.1155/2017/9567498
_version_ 1782511350042329088
author Giudice, Giuseppe
Filoni, Angela
Maggio, Giulio
Bonamonte, Domenico
Vestita, Michelangelo
author_facet Giudice, Giuseppe
Filoni, Angela
Maggio, Giulio
Bonamonte, Domenico
Vestita, Michelangelo
author_sort Giudice, Giuseppe
collection PubMed
description Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB and compare it to the SOC cost. Methods. 20 patients with 14–22% of TBSA with an intermediate-deep thermal burn related injury were retrospectively and consecutively included. 10 of these patients were treated with the SOC, while the other 10 with NXB. The cost analysis was performed in accordance with the weighted average Italian Health Ministry DRGs and with Conferenza Stato/Regioni 2003 and the study by Tan et al. For each cost, 95% confidence intervals have been evaluated. Results. Considering the 10 patients treated with NXB, the overall savings (total net saving) amounted to 53300 euros. The confidence interval analysis confirmed the savings. Discussion. As shown by our preliminary results, significant savings are obtained with the use of NXB. The limit of our study is that it is based on Italian health care costs and assesses a relative small cohort of patients. Further studies on larger multinational cohorts are warranted.
format Online
Article
Text
id pubmed-5331316
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-53313162017-03-14 Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds Giudice, Giuseppe Filoni, Angela Maggio, Giulio Bonamonte, Domenico Vestita, Michelangelo Biomed Res Int Research Article Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB and compare it to the SOC cost. Methods. 20 patients with 14–22% of TBSA with an intermediate-deep thermal burn related injury were retrospectively and consecutively included. 10 of these patients were treated with the SOC, while the other 10 with NXB. The cost analysis was performed in accordance with the weighted average Italian Health Ministry DRGs and with Conferenza Stato/Regioni 2003 and the study by Tan et al. For each cost, 95% confidence intervals have been evaluated. Results. Considering the 10 patients treated with NXB, the overall savings (total net saving) amounted to 53300 euros. The confidence interval analysis confirmed the savings. Discussion. As shown by our preliminary results, significant savings are obtained with the use of NXB. The limit of our study is that it is based on Italian health care costs and assesses a relative small cohort of patients. Further studies on larger multinational cohorts are warranted. Hindawi Publishing Corporation 2017 2017-02-15 /pmc/articles/PMC5331316/ /pubmed/28293640 http://dx.doi.org/10.1155/2017/9567498 Text en Copyright © 2017 Giuseppe Giudice et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Giudice, Giuseppe
Filoni, Angela
Maggio, Giulio
Bonamonte, Domenico
Vestita, Michelangelo
Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title_full Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title_fullStr Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title_full_unstemmed Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title_short Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
title_sort cost analysis of a novel enzymatic debriding agent for management of burn wounds
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://www.ncbi.nlm.nih.gov/pubmed/28293640
http://dx.doi.org/10.1155/2017/9567498
work_keys_str_mv AT giudicegiuseppe costanalysisofanovelenzymaticdebridingagentformanagementofburnwounds
AT filoniangela costanalysisofanovelenzymaticdebridingagentformanagementofburnwounds
AT maggiogiulio costanalysisofanovelenzymaticdebridingagentformanagementofburnwounds
AT bonamontedomenico costanalysisofanovelenzymaticdebridingagentformanagementofburnwounds
AT vestitamichelangelo costanalysisofanovelenzymaticdebridingagentformanagementofburnwounds